VivoSeq
Other

Abemaciclib

0

Pipeline Programs↗

4

Active Trials↗

1

Companies Involved↗

Abemaciclib is an early-stage landscape with 0 programs across 1 company. The most active players are Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

82/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

15

clinical trials

Completed9 · 60%
Recruiting3 · 20%
Withdrawn1 · 7%
Active, not recruiting1 · 7%
Terminated1 · 7%

Clinical Trials

Trial Activity

15 trials

A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC
Recruiting·NNational Taiwan University Hospital·Phase 2·NCT05766410·60 enrolled
ALPINE: Maintenance Letrozole/Abemaciclib
Recruiting·—·Phase 2·NCT06366347·32 enrolled
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
Recruiting·MMridula George, MD·Phase 1·NCT06139107·15 enrolled
Abemaciclib With or Without Atezolizumab for mCRPC
Active, not recruiting·—·Phase 2·NCT04751929·19 enrolled
A Study of Abemaciclib in Healthy Participants
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT02672423·127 enrolled
ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL
Completed·MMedSIR·Phase 2·NCT04603183·162 enrolled
A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without Food
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT02482935·30 enrolled
Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
Completed·JJules Bordet Institute·Phase 2·NCT03339843·85 enrolled
A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT02688088·48 enrolled
A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT02387814·35 enrolled
A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT02884089·40 enrolled
A Study of Abemaciclib in Healthy Participants
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT02677844·35 enrolled
CDK4/6 Tumor, Abemaciclib, Paclitaxel
Completed·YYonsei University·Phase 1/2·NCT04594005·30 enrolled
A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.
Terminated·—·Phase 2·NCT04534283·16 enrolled
Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
Withdrawn·—·Phase 1·NCT03846583

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)